These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. The long-acting dopamine receptor agonist cabergoline in early Parkinson's disease: final results of a 5-year, double-blind, levodopa-controlled study. Bracco F; Battaglia A; Chouza C; Dupont E; Gershanik O; Marti Masso JF; Montastruc JL; CNS Drugs; 2004; 18(11):733-46. PubMed ID: 15330687 [TBL] [Abstract][Full Text] [Related]
6. Predictors of nursing home placement in Parkinson's disease: a population-based, prospective study. Aarsland D; Larsen JP; Tandberg E; Laake K J Am Geriatr Soc; 2000 Aug; 48(8):938-42. PubMed ID: 10968298 [TBL] [Abstract][Full Text] [Related]
7. Olanzapine treatment for dopaminergic-induced hallucinations. Ondo WG; Levy JK; Vuong KD; Hunter C; Jankovic J Mov Disord; 2002 Sep; 17(5):1031-5. PubMed ID: 12360554 [TBL] [Abstract][Full Text] [Related]
8. The association of dopamine agonists with daytime sleepiness, sleep problems and quality of life in patients with Parkinson's disease--a prospective study. Happe S; Berger K; J Neurol; 2001 Dec; 248(12):1062-7. PubMed ID: 12013583 [TBL] [Abstract][Full Text] [Related]
9. Hallucinations and sleep disorders in PD: six-year prospective longitudinal study. Goetz CG; Wuu J; Curgian LM; Leurgans S Neurology; 2005 Jan; 64(1):81-6. PubMed ID: 15642908 [TBL] [Abstract][Full Text] [Related]
10. A neuropsychological longitudinal study in Parkinson's patients with and without hallucinations. Santangelo G; Trojano L; Vitale C; Ianniciello M; Amboni M; Grossi D; Barone P Mov Disord; 2007 Dec; 22(16):2418-25. PubMed ID: 17894370 [TBL] [Abstract][Full Text] [Related]
11. Differential progression of motor impairment in levodopa-treated Parkinson's disease. Goetz CG; Stebbins GT; Blasucci LM Mov Disord; 2000 May; 15(3):479-84. PubMed ID: 10830412 [TBL] [Abstract][Full Text] [Related]
12. Subclinical elevation of plasma C-reactive protein and illusions/hallucinations in subjects with Parkinson's disease: case-control study. Sawada H; Oeda T; Umemura A; Tomita S; Hayashi R; Kohsaka M; Yamamoto K; Sudoh S; Sugiyama H PLoS One; 2014; 9(1):e85886. PubMed ID: 24497930 [TBL] [Abstract][Full Text] [Related]
13. [Study of associated clinical variables and phenomenology of hallucinations in Parkinson's]. Cubo E; González M; Aguilar A; Quintana S Neurologia; 2006; 21(1):12-8. PubMed ID: 16525921 [TBL] [Abstract][Full Text] [Related]
14. Assessment of hallucinations in Parkinson's disease using a novel scale. Wada-Isoe K; Ohta K; Imamura K; Kitayama M; Nomura T; Yasui K; Nakaso K; Nakashima K Acta Neurol Scand; 2008 Jan; 117(1):35-40. PubMed ID: 18095953 [TBL] [Abstract][Full Text] [Related]
15. Double-blind, placebo-controlled, unforced titration parallel trial of quetiapine for dopaminergic-induced hallucinations in Parkinson's disease. Ondo WG; Tintner R; Voung KD; Lai D; Ringholz G Mov Disord; 2005 Aug; 20(8):958-63. PubMed ID: 15800937 [TBL] [Abstract][Full Text] [Related]
16. [Influencing factors of visual hallucinations in patients with Parkinson's disease and its relationship with sleep disorders]. Wu DD; Li SH; Jin LY; Jin Y; Cui YY; Zhao H; Liu HJ; Ma XX; Su W; Chen HB Zhonghua Yi Xue Za Zhi; 2016 Apr; 96(13):1016-20. PubMed ID: 27055793 [TBL] [Abstract][Full Text] [Related]
17. A noninterventional study evaluating the effectiveness of rotigotine and levodopa combination therapy in younger versus older patients with Parkinson's disease. Woitalla D; Dunac A; Safavi A; Ceravolo MG; Gomez Esteban JC; Pavese N; Asgharnejad M; Joeres L; Schuller JC; Chaudhuri KR Expert Opin Pharmacother; 2018 Jun; 19(9):937-945. PubMed ID: 29916262 [TBL] [Abstract][Full Text] [Related]
18. Relationship between age and subtypes of psychotic symptoms in Parkinson's disease. Kiziltan G; Ozekmekçi S; Ertan S; Ertan T; Erginöz E J Neurol; 2007 Apr; 254(4):448-52. PubMed ID: 17401525 [TBL] [Abstract][Full Text] [Related]
19. Neuropsychological correlates of mild to severe hallucinations in Parkinson's disease. Llebaria G; Pagonabarraga J; Martínez-Corral M; García-Sánchez C; Pascual-Sedano B; Gironell A; Kulisevsky J Mov Disord; 2010 Dec; 25(16):2785-91. PubMed ID: 20960483 [TBL] [Abstract][Full Text] [Related]